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ABSTRACT 
The main objective of the research studies presented in this thesis is to study the genetic 
variants and the expression of genes that relate to Multiple Sclerosis (MS). MS is a polygenic 
disease with HLA-DRB1*15:01 allele as a strong risk factor. Currently there are more than 
200 non-HLA regions identified for MS. However, most of the risk loci identified in those 
studies are primarily driven by the relapsing-remitting form of MS (RRMS). To identify risk 
factors specific for the primary progressive form of MS (PPMS) which is a smaller group of 
MS patients, we have examined the exomes of PPMS and RRMS patients matching to 
population based controls in a case-control study setting and reported risk variants and 
mutations that are associated to PPMS and RRMS. 
The context of this study is during the ‘post-GWAS’ era, when researchers are primarily 
focused to understand the functional consequences of the genetic risk factors. Using the 
possibilities of transcriptomic and genotyping data, genes that correlate to the risk loci are 
identified in relevant cell types of MS. Several statistical methods are implemented to 
characterize the risk loci and replicate the findings in the context of disease. MicroRNAs 
(miRNAs), small non-coding RNAs which regulate gene expression at post-transcriptional 
level, have been identified dysregulated in autoimmune diseases, including MS. We used 
experimental autoimmune encephalomyelitis (EAE), a commonly used animal model for MS 
to understand the role of miRNA in the immune activation of EAE.  
Next generation sequencing (NGS) methods were widely applied in all of these studies 
specifically at transcriptomic and genomic level of the disease. NGS methods are data 
intensive but have higher reliability. To test the reliability, we compared reported gene 
expression measurements for ostensibly similar tissue samples collected from different RNA-
seq studies. We found an overall consistency on expression data obtained from different 
studies and identified the factors contributing to systematic differences. This thesis gives an 
overview of progresses happening in the area of MS genetics, EAE model for 
neuroinflammation and omics data analysis to address genetic regulation of disease. 
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1 INTRODUCTION 
 
1.1 MULTIPLE SCLEROSIS 
Multiple sclerosis (MS) is a chronic inflammatory disease of the central nervous system 
(CNS) leading to demyelination and neuronal loss which was first described in 1868 by a 
French neurologist Jean-Martin Charcot [1]. It is one of the leading cause of neurological 
disability among young adults worldwide, with a prevalence of 0.19% in Swedish population 
and a female to male incidence ratio of 2.26 [2]. MS is initiated by infiltration of immune 
cells across the blood brain barrier (BBB) leading to demyelination and neuronal loss with 
inflammatory lesions [3]. The variation in clinical manifestations in MS and different 
symptoms such as disturbances of motor function, sensation and vision depend to a large 
extend on the site of lesions within the CNS [4]. 
 
For diagnosis of MS based on McDonald criteria, two episodes of demyelinating attacks 
separated by time is required [5]. A first episode suggestive of MS is called Clinically Isolated 
Syndrome (CIS). To establish a diagnosis of MS, magnetic resonance imaging (MRI) to 
visualize the presence of brain lesion and expanded disability status scale (EDSS) help to 
determine the  functional states of MS patients [5]. Around 90% of patients have oligoclonal 
bands and 70% of patients have increased levels of IgG in the Cerebrospinal fluid (CSF) 
[6,7]. About 85% of MS patients have relapsing remitting form of MS (RRMS) with repeated 
episodes of neurological symptoms. With time from disease onset, many of these patients 
accumulate neurological disability and progress to a more progressive form of MS called 
secondary progressive MS (SPMS) [8]. However, in cases of 10 to 15% of patients a 
progressive accumulation of disability from the disease onset are observed and are 
categorized as primary progressive MS (PPMS) (Figure 1). The current immunomodulatory 
treatments doesn’t effectively halt progressive form of MS, however reduces the episodes of 
relapses [9]. 
 
MS is a complex disease in which genetic, environmental, epigenetic and life style factors 
determine the risk for disease susceptibility [10]. Many of these risk factors are found in 
healthy persons and moreover not all of these risk factors are present in any one MS patient, 
signifying the heterogeneous nature of the disease. To add to this complexity there is a 
component of genetic heterogeneity, implying that patients carrying similar clinical 
phenotypes can have different combination of risk genes for MS disease. In addition to risk 
genes, epigenetic factors and changes in gene expression or non-coding RNA can contribute 
towards developing this complex disease [11].  
Although multiple factors influence the initiation of the disease, there exist a complex, 
multicellular pathophysiological process during disease progression of MS [3]. One of the 
generally accepted hypothesis is that MS is mediated by activated autoreactive myelin-
specific T cells that infiltrate into the CNS, resulting in a chronic inflammatory response [8]. 
It is supported by genetic association of Human leukocyte antigen (HLA) class II molecules 
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and its presentation of CNS specific autoantigens to autoreactive T cells. Moreover, 
demyelinating lesions obtained from MS patients contain CD4+ and CD8+ T cells in addition 
to monocyte-derived macrophages and occasionally plasma cells [12]. There is also evidence 
suggesting a pathogenic role of autoreactive B cells [13]. After differentiating of B cells into 
plasma cells, it produce autoantibodies which are specific for myelin basic protein 
autoantibodies (MBP) and myelin oligodendrocyte glycoprotein (MOG) autoantibodies [14]. 
Moreover, patients with MS have immunoglobulin G oligoclonal bands (OCBs) in the form 
of B-cell activation in their cerebrospinal fluid (CSF) which is also a biomarkers used 
clinically for the diagnosis of MS [15]. Though the exact mechanism of B cells is unknown 
in MS, several anti-CD20 depleting drugs that target B cells such as Rituximab, Ocrelizumab 
and Ofatumumab have proven to be effective treatment of MS and provide more diverse and 
personalized treatment options for patients with MS [16].   
 
Figure 1: Progression and different phases of MS disease 
[Figure reproduced from “Olsson, T. et al. (2016) Interactions between genetic, lifestyle and 
environmental risk factors for multiple sclerosis Nat. Rev. Neurol. doi:10.1038/nrneurol.2016.187”] 
 
1.1.1 Genetics of Multiple Sclerosis 
The human genome have more than three billion bases of DNA and its variation leads to 
genetic differences between individuals and populations. The common form of variation in 
the genome is the single nucleotide polymorphisms (SNPs) and imply a one-base at a fixed 
position in the genome [17]. A minor subset of SNPs correlates to the phenotypic differences 
including disease susceptibility and progression within and between populations. In addition 
to SNPs there are other classes of DNA variations that correlate to the observable phenotypes 
in the genome. These variations include large regions of variable copy number termed as 
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copy number variants (CNVs) and small variation or polymorphisms in the form of 
nucleotide Insertion and Deletion (INDELs). INDELs often appear to be in linkage 
disequilibrium (LD) with surrounding SNPs. These variants are widespread across the 
genome and can be found in both coding and non-coding sequences with varying frequencies 
across different populations [18]. If a variant found in the coding sequence alter the 
nucleotide triplets, called codons, resulting in an amino acid change of a protein molecule, 
the variant is defined as non-synonymous and conversely if it doesn’t alter the amino acid 
sequence, it is defined as synonymous variant. Besides the direct alteration of protein through 
nucleotide change in the coding region, SNPs in non-coding region can vary the phenotype 
through transcriptional regulation or epigenetic control [19].  
MS is a polygenic disease with one major risk loci in the HLA region. The genetic basis of 
MS was first demonstrated in familial aggregation studies and the overall proband-wise 
concordance rate for monozygotic twins was 18.4 which was significantly higher than for 
dizygotic twins at 4.6 and siblings at 2.7 [20]. However, a recent familial MS risk study based 
on Swedish population found a proband-wise concordance rate for dizygotic twins with same 
sex at 3.3 and observed a higher transmission rate of disease from fathers to sons compared 
to mothers to sons, suggesting the role of less prevalent sex in the disease transmission. The 
heritability estimated at 0.64 and the shared environmental component calculated to be 0.01, 
implies that genetics play an important role [21]. 
 
1.1.1.1 HLA and MS susceptibility  
HLA genes located on chromosome 6p21 were the first reported genetic risk for MS which 
was identified through a hypothesis driven approach [22]. HLA gene complex encodes major 
histocompatibility complex (MHC) proteins in humans which have an important role in the 
regulation of immune system. MHC region in mammals are the most genetically variable 
coding loci and in humans there are currently 18,955 HLA and related alleles reported in the 
HLA database [23]. Based on its function, HLA genes are classified into three broad classes. 
HLA genes corresponding to MHC class I (A, B and C) are expressed in cell surface in most 
of the nucleated cells and can present self-peptides and intracellular pathogens including 
viruses to cytotoxic T-cells. HLA genes corresponding to MHC class II (DP, DM, DO, DQ, 
and DR) are expressed on the surface of antigen-presenting cells (APCs) and present peptides 
from extracellular components that can be degraded by the APCs. These particular antigens 
stimulate T-helper cells which in turn stimulate antibody-producing B-cells to produce 
antibodies to that specific antigen. HLA genes corresponding to MHC class III encode several 
components of the complement system (C2, C4a, C4b and Bf). Complement proteins have a 
role in activating and maintaining the inflammatory process of an immune response. 
The HLA corresponding to class II allele variants — DRB1*15:01, DRB5*01:01, 
DQB1*06:02 and DQA1*01:02 show the strongest genetic association with MS. The 
DRB1*15:01 haplotype increases the MS risk by about 3-fold [24]. Although it has been fairly 
easy to identify MS associated haplotypes, it has been harder to identify which alleles on 
haplotype is responsible for the association. This is because of high LD in the HLA region. 
HLA corresponding to class I allele variants HLA-A*02 have a protective effect in MS [25].  
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Figure 2: Association of 201 non-HLA SNPs (including chromosome X) on MS Chip study 
[33] and their corresponding eQTL genes. Red color in the cytogenic bands means telomere 
and blue color means centromere of the chromosome. 
chr11
rs35218683 (IFITM3)
rs61884005 (PDE3B,RRAS2)
chr11:14868316 (CYP2R1)
rs1365120 (PRR5L)
rs2269434 (ACP2,DDB2,MTCH2,MADD,
PSMC3,DDB2,MYBPC3,NR1H3,RAPSN,SPI1)
rs4939490 (CD5,CD6)
rs11231749 (CCDC88B,RPS6KA4,FKBP2,GPR137,PLCB3,RPS6KA4,VEGFB)
rs531612 (C11orf68,CTSW,EFEMP2,SNX32,
FIBP,BANF1,CCDC85B,CST6,SF3B2,FOSL1,SART1,TSGA10IP),
rs4409785 (FAM76B,SESN3)
rs56095240
rs34026809 (CXCR5,TMEM25,DDX6)
rs12365699 (CXCR5,DDX6,TMEM25)
rs6589706 (CXCR5,DDX6,TMEM25)
chr11:118783424 (MLL)
rs6589939 (UBASH3B)
rs4262739 (ETS1)
chr12
rs1800693 (TNFRSF1A,U47924.1)
rs12832171 (TNFRSF1A)
rs2364485 (LTBR)
rs7977720 (CLEC2D,CLECL1)
rs701006 (B4GALNT1,CYP27B1,MARCH9,METTL21B,
XRCC6BP1,TSPAN31,OS9,TSFM)
rs61708525 (PLXNC1)
rs3184504 (CUX2,ALDH2,HECTD4,SH2B3,TRAFD1)
rs7975763 (CDK2AP1,MPHOSPH9,OGFOD2,SETD8,
SNRNP35,C12orf65,PITPNM2,RILPL2,SBNO1)
chr13
rs9591325 (DLEU7,ST13P4)
rs9568402
chr13:100026952 (MIR548AN,
TM9SF2,TM9SF2)
chr14
rs11852059 (FRMD6,GNG2,GNG2)
rs12434551 (ZFP36L1)
rs34695601 (BATF,FLVCR2)
chr14:88523488 (GALC)
rs12588969 (TRAF3)
rs12147246 (TRAF3)
chr16
rs405343
rs2286974 (CLEC16A,DEXI)
chr16:11213951 (CLEC16A,DEXI)
chr16:11353879 (RMI2)
rs34947566 (CLEC16A,RMI2)
rs3809627 (FAM57B,GDPD3,
PPP4C,TBX6,YPEL3)
rs8062446 (NLRC5)
rs12925972 (DYNLRB2,WWOX)
rs17724508
rs6564681
rs35703946 (IRF8,LINC01082)
chr15
rs62013236 (CTSH)
rs6496663 (IQGAP1)
chr20
rs4812492 (LPIN3,PLCG1,TOP1)
rs4812772 (TOX2)
rs6032662 (CD40,SLC12A5,NCOA5)
rs6020055 (B4GALT5,SLC9A8)
rs2585447
rs2248137 (BCAS1,CYP24A1)
rs6742 (ZGPAT)
chr17
rs4796224 (DHRS11,GGNBP2,MRM1,MYO19,PIGW,GGNBP2,MYO19)
rs9909593 (GSDMB,ORMDL3,PGAP3,GSDMA,IKZF3,ZPBP2)
rs883871 (THRA,NR1D1)
rs1026916 (STAT3)
rs7222450 (MAP3K14)
rs11079784 (C17orf57,EFCAB13,TBKBP1,C17orf57,NPEPPS)
rs2150879 (MIR21,RNFT1,TUBD1,HEATR6,BCAS3,VMP1)
rs9900529 (GGA3,GRB2,MIF4GD,MRPS7,NUP85,
CASKIN2,MYO15B,MIF4GD,SLC25A19,TSEN54)
chr19
rs12971909 (HDGFRP2,UBXN6)
rs1077667 (C3,TNFSF14)
rs34536443 (ICAM3,TYK2)
rs28834106 (KEAP1,KRI1,PDE4A,SMARCA4)
rs12609500 (ATG4D,SMARCA4)
rs58166386 (C19orf44,CALR3,EPS15L1)
rs4808760 (IFI30,PDE4C,KIAA1683,MAST3,MPV17L2)
rs7260482 (PVR)
rs11083862 (HIF3A)
rs1465697 (CD37,TEAD2,DKKL1,SLC6A16)
chr22
rs9610458 (MAPK1,PPM1F,TOP3B)
rs4820955 (LIMK2,PIK3IP1,PISD,SFI1)
rs760517 (CSF2RB,NCF4,PVALB)
rs5756405 (CSF2RB,NCF4)
rs137955 (ENTHD1,GRAP2)
rs140522 (CHKB,TYMP,NCAPH2,SCO2,CPT1B,ODF3B)
chr18
rs4940730 (ALPK2)
rs9955954 (MALT1)
rs2469434 (CD226)
chr21
rs9808753 (IFNGR2,TMEM50B,ITSN1)
rs2836438 (ERG,TMPRSS3)
chrX
rs2807267
 6 
For a long time HLA has been considered as the only reproducible genetic risk factor in MS 
[26,27]. However,  a recent study using a high-resolution mapping of HLA region has identified 
new associations in addition to the previous finding in class II risk alleles (HLA-DRB1*15:01, 
HLA-DRB1*13:03, HLA-DRB1*03:01, HLA-DRB1*08:01 and HLA-DQB1*03:02) and 
class I protective alleles (HLA-A*02:01, HLA-B*44:02, HLA-B*38:01 and HLA-B*55:01) 
[28]. 
1.1.1.2 Mapping MS risk genes based on large scale association studies 
The landscape of genetics has changed remarkably by utilizing the possibilities of consortia 
based efforts, in particular genome wide association studies (GWAS) which include 
thousands of individual samples using new generation of genotyping platforms. The GWAS 
is a hypothesis-free approach in which SNPs tagging to the LD blocks across the whole 
genome are included on a genotyping array. Large sample sizes of cases and controls and 
measures for controlling for population stratification are important to perform well-powered 
GWAS.  
The first MS-GWAS was performed by the International Multiple Sclerosis Genetics 
Consortium (IMSGC) using trio families, replicating in a case-control study and found two 
risk alleles outside the MHC region, mapping to the IL7R gene and IL2RA gene [29].  A 
second modestly powered GWAS for MS identified 29 novel non-HLA loci and three 
additional HLA loci and replicated 28 non-HLA loci and four HLA loci that were previously 
reported in different association studies [30]. GWAS chips contain only tag SNPs for 
common variants present in a population. To identify relevant SNPs that are associated to 
MS and to replicate the previous GWAS signals, ImmunoChip a custom-made genotyping 
array fine mapped on risk loci of eleven different autoimmune or inflammatory diseases was 
used [31]. The ImmunoChip study analysed 14,498 subjects with MS and 24,091 healthy 
controls for 161,311 autosomal variants and established 110 MS associated risk loci. 
Bayesian fine mapping was applied to refine these associations [32]. These large scale genetic 
studies resulted in the discovery of many non-HLA variants associated to MS disease. 
However the effect size of these non-HLA disease associated variants are smaller compared 
to the effect size of the variants that are strongly associated in the HLA region. A recent study 
(MS Chip study), analysed  47,351 multiple sclerosis (MS) subjects and 68,284  healthy 
subjects and reported 200 independent autosomal susceptibility variants including one 
variant in X chromosome and 32 independent associations within the HLA region [33]. In 
this study meta-analysis of several GWAS in MS was done in discovery part, followed by 
replication in independent cohort. Most of the loci found in this study are in close proximity 
to the immune-related genes which suggests them as potential candidate genes for 
involvement in pathogenesis of MS (Figure 2). 
1.1.1.3 Missing heritability and rare variants  
For many traits, large scale association studies have turned out to be highly successful with 
24,218 unique SNP-trait associations from 2,518 publications reported in the NHGRI Catalog 
[34]. However these identified variants explain only a modest proportion of the total 
heritability. In genetics there has been much emphasis on so-called 'missing heritability' of 
traits. Some of the effects related to the missing heritability are contributed by epistatic (i.e. 
non-additive) interactions, so that the common variants contribute more risk in combination 
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than independently [35]. One of the other possible explanation is that these large scale 
association studies have only investigated common SNPs with a minor allele frequency (MAF) 
above 5% and lack proper knowledge of rare variants relevant in the disease which cannot be  
imputed by LD to the common variants present on the genotyping arrays. It has also been 
suggested that rare monogenic sub-phenotypes may exist for each common disease (Figure 3) 
[36].  
A recent meta-analysis based on 32,367 MS cases and 36,012 controls analysed 144,209 low-
frequency coding variants (MAF < 5%) genotyped using exomechip found four novel variants 
associated to MS independent of common variant signals found in previous studies (Figure 3). 
These novel genes have a key role for regulatory T cell homeostasis and regulation, IFNγ 
biology and NF-κB signaling in MS pathogenesis [37].  
 
 
Figure 3: Spectrum of Disease Allele Effects. Scales in the axis are not linear. Genes marked 
in red are the genes with low-frequency coding variants studied in MS with exome chip [37].  
 
 
1.1.2 Characterization of genotype-phenotype relationships in MS 
Since many of the disease associated variants are located in the non-coding region of the 
genome and are synonymous or nonsense mutations (i.e. not changing the protein structure), 
the function and mechanisms of each of these variants are unknown [38]. This suggests that 
most of the common variants associated to the disease have regulatory functions [39]. 
Moreover, hundreds of genetic variants have been identified for many of the diseases, it is not 
feasible to knock-down or overexpress each of the genes within the risk loci. To identify the 
genes that are regulated by variants, Jansen and Nap in 2001 proposed the concept of “genetical 
genomics”, by correlating variants to the intermediate molecular quantitative traits which 
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include gene expression, methylation or protein levels [40]. ‘Genetical genomics will combine 
the power of two different worlds in a way that is likely to become instrumental in the further 
unravelling of metabolic, regulatory and developmental pathways’, Jansen RC and Nap JP 
(2001) [41]. 
1.1.2.1 From SNPs to genes — eQTL and ASE 
Genes can be assigned to disease variants in different ways. A gene can be assigned to the SNP 
through its proximity or through a statistical or functional association with the gene. Since gene 
expression levels are strongly heritable (heritability in humans 0.25) and specific to tissues, it 
can be reliably mapped to the SNPs in different tissues [42]. Depending on the distance from 
the proximity of the SNP, eQTLs can act locally (cis) or at a distance (trans). cis-eQTL SNPs 
are located close to the transcription start site (TSS) of genes. However, for distance various 
measures have been used in different studies ranging from 5kb to 500 kb [43–45]. There is an 
increased probability of finding cis-regulated genes at closer distances to the variant and 
number of tests can be reduced by selecting fewer genes. This can also reduce multiple 
simultaneous statistical tests which is a drawback in trans-eQTL studies where the genes across 
different chromosomes are required to be tested (Figure 4). Moreover, trans-eQTL often 
requires very large sample size to reach statistical significance [43,46]. 
 
Figure 4: Possible mechanism of eQTL local effects (cis-eQTLs) and distant effects (trans-
eQTL) [Figure reproduced from “Westra HJ, Franke L. From genome to function by studying eQTLs. 
Biochimica et Biophysica Acta - Molecular Basis of Disease. 2014. doi:10.1016/j.bbadis.2014.04.024”] 
 
Cis-eQTL approach has its own fundamental limitations in disease study [47]. First, due to the 
LD it is challenging to identify the regulatory variant from neighbouring variants in moderate 
to high LD. Second, the expression of a gene can be influenced by multiple genetic, epigenetic 
and environmental or treatment factors. This suggests that eQTL effects may act in a context 
specific manner. Third, for a given variant with small effect size or with low allele frequency, 
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the study requires a large sample size to identify the effect. In study III of this thesis, different 
approaches and genetic statistical methods are implemented to address these concerns [48]. A 
complementary approach to find genetic variants associated to gene expression is based on 
allele-specific expression (ASE). In ASE, a regulatory variant which can be heterozygote can 
show different level of expression at gene level or transcript level [49]. Compared to analysing 
total expression levels in eQTL studies, in ASE the two alleles expressed at the same cellular 
environment and trans-acting environmental factors that can potentially increase variation 
between samples and individuals are minimized [50]. However, ASE is influenced by the local 
LD structure and level of allelic heterogeneity [47]. Therefore, these methods need to be 
implemented with caution where genomic loci are highly polymorphic, for example at HLA 
and T-cell receptor regions of the genome. 
 
1.2 EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS 
Experimental autoimmune encephalomyelitis (EAE) is a widely used animal model to 
understand the mechanisms of inflammation in the CNS and role of the MS risk genes in vivo 
is studied in EAE models with the opportunities of gene targeting in mice [51]. Besides MHC 
locus in EAE, around 50 QTLs (Quantitative Trait Locus) have been reported to mediate EAE  
[52]. Some of the identified genes in both EAE and MS include genes in the MHC class II 
transactivator (CLEC16A) and Il22ra2  [53–56].  
To study the genetic regulation of neuroinflammation we have used two different inbred rat 
strains of EAE and recombinant MOG with incomplete Freund’s adjuvant without pertussis 
toxin or mycobacterium is used to induce EAE [57]. In our study, to understand the regulation 
in miRNA in EAE (study I) we used the EAE-susceptible Dark Agouti (DA) rat strain and the 
Piebald Virol Glaxo (PVG) rat strain with identical MHC which is resistant to MOG induction. 
After the MOG induction an immune response in the secondary lymphoid organs is found in 
both strains but in DA rats the activation from myelin antigen become pathogenic in nature 
within 10-12 days. In DA rats the disease is characterized by demyelination in the CNS. An 
assessment for EAE scoring is done based on visual inspection of clinical symptoms such as 
ascending flaccid paralysis and measurements of weight loss. 
The advantage of the animal model like EAE for neuroinflammation is the accessibility of 
appropriate tissues and target organ to study the disease pathogenicity and progression, which 
is difficult to obtain in human MS. In study I, we have collected the tissues from lymph node 
at different time points after the EAE immunization in DA and PVG rats. EAE is also 
characterized by lesions in CNS. However, compared to MS where lesions are found in brain 
which characterize the disease symptoms, in EAE the most affected site is the spinal cord. EAE 
model has provided an invaluable tool for development of new treatments against MS, 
including natalizumab [58] and glatiramer acetate and helped to understand the inflammatory 
process during the course of the disease [59]. However, there are certain therapies that had 
opposite outcomes in EAE compared to MS, for example administration of anti-tumour 
necrosis factor and interferon (IFN)-γ had adverse effect in MS patients [60]. 
In EAE myelin-specific T cells are activated in the periphery and infiltrate into the CNS 
through BBB [61–63]. In CNS the T cells are reactivated by infiltrated and local activated 
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antigen-presenting cells (APC), presenting major histocompatibility complex (MHC) class II 
associated peptides, leading to inflammation, demyelination and axonal damage. Studies from 
different models of EAE have shown evidence that T cells specific for self-antigens regulate 
the disease. Cytokine environment found in the draining lymph nodes during T cell receptor 
(TCR) stimulation is important for T cell differentiation. Until recently it was thought IFN-γ 
producing T helper type 1 (Th1) cells were the main effector T cells responsible for 
autoimmune inflammation [64]. Recent studies have highlighted the importance of IL-23 for 
EAE induction and autoimmune inflammation in human brain[65]. This led to the 
identification of IL-23-induced Th17 cells that produce IL-17, in addition to IL-17-secreting 
γδ T cells as a major effector cytokine [66,67]. Besides regulatory T cells, EAE was used to 
establish the role of B cells [68]. 
1.2.1 microRNAs in EAE and MS 
microRNA (miRNA) is a small (about 22 nucleotides), single stranded non-coding RNA 
molecule which functions in RNA silencing and post-transcriptional regulation of gene 
expression[69]. Expression of more than 60% of human genes can be changed by miRNAs and 
similar to cytokines in immune regulation, miRNA function is characterised by pleiotropy  
where a single miRNA can target to many mRNAs and expression level of a mRNA can be 
regulated by many miRNAs, resulting in a complex regulatory network [70]. miRNAs are key 
regulators of the immune response, antibody secretion and release of inflammatory mediators 
and functional role in autoimmune diseases[71]. They have specific roles in both innate and 
adaptive immunity. A decline in the amount of Dicer or Drosha (essential enzymes for miRNA 
biogenesis) in regulatory T cells, can result in development of autoimmune diseases[72]. 
miRNA lacking CD4+ T cells failed to differentiate into Treg cells in the thymus. MIR155 
knockout mice upon autoimmune inflammation were shown to be resistant to EAE due to 
reduced differentiation of Th1 and Th17 cells [73]. A recent study have also shown that 
expression of 56 miRNAs found in oligodendrocytes of EAE mice was lower compared to 
normal mice [74]. These increasing evidence shows that miRNAs are involved in various 
pathological conditions, including autoimmune inflammatory processes.  
 
1.3  THE ERA OF OMICS 
“Omics”, a suffix generally referring to the global measurement and analysis of a given level 
of biological information, encompasses the application of omics platforms range from 
genomics (identification of genes), transcriptomics (gene expression), epigenomics 
(epigenomic factors), proteomics (protein abundance), metabolomics (metabolites and 
metabolic networks) and pharmacogenomics (genetics effect on drug response)[75]. These data 
resources provide knowledge about molecular pathways in cells and their role in diseases. 
Presently, state-of-the-art next-generation sequencing (NGS) and multiplexed array 
technologies have enabled the large scale generation of experimental and clinical datasets [76]. 
Studies I to III of this thesis have utilized NGS methods within the scope of genomics and 
transcriptomics (including small RNA sequencing) to test various hypothesis related to MS and 
neuroinflammation in EAE.  
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Many large scale projects such as 1000 Genomes Project [77], ENCODE [78], ImmGen [79], 
TRANSFAC [80], Human Protein Atlas [81] etc have aimed to investigate biological systems 
at different levels generating large scale heterogeneous datasets with better annotation for the 
scientific community [82]. In all the studies included in this thesis we have utilized the potential 
publicly available datasets in an integrative manner to improve and refine the primary findings. 
 
1.3.1 Genomics 
Current array-based genotyping covers around 2.2 million SNPs, which is about ~2% of total 
common SNPs and have been widely used in many disease association studies including 
GWAS [83,84]. Two platforms— Illumina (San Diego, CA) and Affymetrix (Santa Clara, CA), 
have been primarily used for GWAS. Illumina platform is based on a bead-based technology 
with a longer DNA sequences to detect alleles. Affymetrix have slightly shorter DNA 
sequences printed to a chip as a spot which detect a specific allele by differential hybridization 
of the sample DNA [85]. GWAS is based on Common Disease Common Variant hypothesis 
which implies that common diseases are regulated by the genetic variants that are common in 
population. If common variants are associated with a complex disease, the effect size 
(penetrance) must be small compared to that found in rare disease. Moreover, if the common 
variants have small effects (low penetrance) and if common diseases show heritability, then 
multiple common variants must regulate disease susceptibility. This suggests that the total 
genetic risk due to common variants spread across multiple genetic factors, prompting 
population-based studies in genome-wide scale compared to traditional family-based genetic 
studies [86]. Allele frequency of a variant and effect size of that potential disease variant are 
the key factors to be considered in addition to the sample size required to identify statistically 
significant genetic effects. Apart from common variants designed for GWAS these platforms 
also provide customized chips designed based on the region of interest (eg. ImmunoChip and 
MS Chip) or low-frequency variants (eg. Exomechip) [32,33,37]. In study III, for eQTL studies 
we have used genotyping data obtained from ImmunoChip and MS Chip. 
Contrarily, Whole Genome Sequencing (WGS) method assays every nucleotide, resulting in 
several million variants including rare variants [87]. For cost advantage, low coverage 
sequencing (e.g. 4X average) is often preferred in WGS to maximize the cohort size. This 
increases the error rates for low coverage WGS to 15% or higher for discovery of variants [84]. 
As the cost of WGS become affordable, it will be the most promising technique to apply in 
large scale genetic studies [88]. Currently, compared to WGS the cost of Whole Exome 
Sequencing (WES) is lower and its promise is based on success of targeted gene sequencing 
studies and discovery of rare variants in the protein coding region with better coverage[89]. 
Since mutations are occurring in protein coding genes at a rate of ~1 × 10-5 per gene on a 
generation of nonsynonymous variants, every gene is expected to harbour functionally 
important variants which can be identified by sequencing. Moreover, potential genes 
underlying complex traits can be studied using WES and functional annotation of coding 
variants are usually simplified and straightforward in this approach [90]. 
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1.3.2 Transcriptomics 
To quantify the amount of mRNA in a sample several methods exist starting from northern 
blots and real-time PCR on single gene to microarrays and RNA sequencing (RNA-Seq) at 
global level. All these methods are different based on the range of gene expression measured 
and techniques used to detect the expression levels. Compared to other platforms, RNA-Seq 
does not depend on a pre-designed probe sequences, it lacks issues related to probe redundancy 
and annotation and thereby improves interpretation of the data. Though RNA sequencing 
achieved high resolution on the transcript architecture, the utility of other platforms is not 
undervalued and the selection of the platform purely depend on the study design and cost factor 
[91,92]. The application of PCR and RNA-Seq methods has expanded to include small RNAs 
and in study I, we have applied NGS methods to profile miRNAs and exon arrays to identify 
gene expression in EAE. Recent studies have shown that for high-resolution eQTL analysis, 
RNA-Seq can be considered as a ‘gold standard’, allowing a joint analysis of variation in gene 
expression levels and allele-specific expression across individuals [93,94]. In study III, we have 
applied RNA-seq to study the transcriptome of MS patients and disease eQTLs. 
   
1.3.3 Omics data analysis and approaches 
High-throughput ‘omics' technologies enable the efficient generation of massive and complex 
datasets. Compared to the classical settings where very few specific null hypotheses are tested, 
the high-throughput nature of these technologies have resulted in the simultaneous analysis of 
very large number of variables (e.g. number of genes in expression or SNPs in array) compared 
to the number of independent subjects (e.g. clinical samples). This has resulted in simultaneous 
testing of many hypotheses, each subjected to a decision error (type I and type II errors), which 
requires careful adjustments in the form of multiple testing. To avoid overfitting and 
collinearity, classical statistical method requires the number of independent subjects to be large 
than the number of variables [95]. However, in omics based experiments the number of subjects 
are often limited due to economic and technical limitation of the experiments and therefore 
new statistical methods had to be applied specific to the experimental design and hypothesis 
under test. In study I to III, we have implemented different statistical methods in omics data 
analysis to test different hypothesis with better accuracy and significance. 
In the exploratory phase of the analysis, dimension reduction and cluster detection approaches 
are commonly used in omics dataset [76,96]. While dimension reduction uncover the global 
variance within and between variables of dataset, cluster analysis explores the pairwise distance 
between the subjects for its relationships. These methods can explain the correlated structure 
of the data thereby identify the technical artefact such as batch effects or explain the 
characteristics of the outliers in the cluster analysis [97]. These methods are trivial while 
assessing the reproducibility, validity and interpretation of ostensibly similar omics data 
generated under different environments or stimuli. In study IV, we have used the possibilities 
of dimensional reduction and cluster detection to address reproducibility of the transcriptome 
data collected from different lab settings and platforms.  
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Depending on the omics platform and datatype the initial data processing steps and 
normalization procedures varies. Integration of different types of omics data in the context of 
a disease have a higher informative power compared to a single isolated omics data [98,99]. A 
single type of omics data can provide differences associated to a disease which can be reflecting 
either reactive process or causative factors [100]. To identify causative factors that lead to 
disease or to understand the disease mechanism, the integration aspect have a much wider scope 
as shown in this MS disease study [101]. In study III, we have applied a “genome first 
approach” where I assume that a disease associated variant contribute to disease rather than 
being the consequence of disease. These disease variants can be a direct source of risk 
prediction; however it may not suggest a particular gene or pathway that regulate the disease. 
To this end, a disease variant centered integration of additional omics data types such as 
transcriptome, DNASE etc, can imply the importance of the casual loci and pathways 
contributed to the disease. 
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2 THESIS AIMS 
 
The general aim of the thesis was to  study genetic risk factors for MS and to characterize its 
genetic regulation in humans and experimental model for neuroinflammation, utilizing next-
generation sequencing methods. 
 
Specific scientific goals: 
Study I: To investigate different miRNAs regulated during pathogenic autoimmune 
neuroinflammation. 
 
Study II: To identify different genetic variants associated with PPMS and RRMS 
 
Study III: To gain further insights into the downstream effects of MS associated variants 
utilizing cis-eQTL based methods in patient derived primary cells and immune cells. 
 
Study IV: To test the consistency among a set of publicly available RNA-Seq datasets 
obtained from similar tissues generated at different laboratories using different strategies. 
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3 METHODOLOGICAL CONSIDERATIONS 
This thesis includes different bioinformatic methods, experimental techniques and cohort 
based dataset, which are described in detail in the included studies. Here I elaborate some 
of the relevant methods and approaches used for different studies in this thesis. 
3.1 MIRNA PROFILE OF EAE AND ITS REGULATION 
3.1.1 Small RNA sequencing and differential expression 
After sequencing, small RNA sequence reads are demultiplexed to their corresponding samples 
and adapter sequence was trimmed from the read. In case of incomplete adapter sequence, a 
minimum adapter size of 8 bases was selected. The reads of length 12-42 bases were mapped 
to known miRNA of the miRBase repository (version 16.0) and miRNAs were quantified in 
terms of Reads per Million (RPM) with miRanalyzer tool using default settings [102,103]. For 
differential expression of miRNAs student t-test was applied and significant differentially 
expressed miRNAs were selected based on p value (p < 0.05) and expression values (RPM 
>1000). For low expressed miRNAs (RPM < 1000), fold change (|FC| >1.5) was considered as 
an additional selection criteria. 
3.1.2 miRNA target prediction and pathways in disease regulation 
Limited knowledge on the mechanism of mRNA degradation by miRNA, poses development 
challenges for miRNA prediction tools. Genes regulated by differentially expressed miRNAs 
in EAE were studied using prediction tools. Several tools are developed considering the 
parameters such as seed sequence complementarity, site accessibility, sequence conservation, 
thermal stability of the miRNA:mRNA interaction etc, and to a wider extend these tools differ 
in their algorithms resulting in slightly different prediction. Considering these aspects, common 
gene targets predicted by two well established target prediction tools— TargetScan and 
miRanda were selected [104,105]. TargetScan is highly precise among the sequence-based 
tools, but have low sensitivity resulting from a high false negative rate. miRanda has better 
sensitivity but has a higher false positive rate [106]. To understand the regulation miRNA 
targets (genes) that are differentially expressed in EAE in the DA and PVG strains were 
selected for further functional analysis. This also improves the identification of relevant and 
true target mRNAs.  
Using Ingenuity Pathways Analysis (IPA, https://www.qiagenbioinformatics.com/), relevant 
pathways regulated by differentially expressed genes targeted by miRNA were identified 
which can indicate downstream consequences of miRNA dysregulation in EAE. 
3.2 WHOLE EXOME SEQUENCING STUDY ON MS PATIENTS 
3.2.1 MS Cohorts for case-control study  
The Genes and Environment in MS (GEMS) is a cohort based study in which a subset of cases 
in the Swedish Neuroregistry fulfilling the McDonald criteria were included besides prevalent 
cases of MS [107]. Epidemiological Investigations in Multiple Sclerosis (EIMS) is a population 
based case-control study of incident MS cases identified in neurology clinics throughout 
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Sweden [108]. IMSE cohort includes MS patients who were treated with Natalizumab [109]. 
In GEMS, EIMS and IMSE cohorts the controls are matched for age, sex, and residential area 
and are recruited from entire Sweden. For STOP-MS cohort, MS patients were recruited at the 
Karolinska University Hospitals based on Poser criteria or McDonald criteria for MS 
[110][5,111]. The controls include patients with other neurological diseases (ONDs) which can 
be either non-inflammatory or inflammatory. Subjects for study II were selected from the 
GEMS, EIMS, IMSE and STOP-MS cohorts. All PPMS samples included in the case-control 
study were matched to population based controls (PBC) based on age, gender and ethnicity. 
Gender and ethnicity were matched to the RRMS cases. Ethnicity information regarding 
individuals and their parents were obtained based on questionnaire data reported by the 
individuals.  
3.2.2 SNP and CNV calling pipeline 
In study II, genomic variants, such as SNPs and INDELs were identified using GATK v3.6 
pipeline which primarily includes data pre-processing steps and variant discovery using variant 
calling  and variant recalibrations algorithms [112]. The data pre-processing for GATK pipeline 
steps include mapping of sequence reads using BWA-MEM alignment tools and base 
recalibrations [113]. Gaussian mixture model (GMM) implemented in variant quality score 
recalibration (VQSR) step of GATK pipeline is applied to compare the quality of the variants 
in this study to highly validated variant resources (omni, 1000 Genomes, hapmap and dbSNP), 
thereby estimating the sensitivity and specificity for the variant calls. An optimal Transition to 
Transversion (Ti/Tv) ratio for exome sequencing is used to remove the false-positive variant 
calls in VQSR step [114]. A total of 1708 subjects were retained after exome mapping and 
variant calling step. 
For copy number variants (CNVs) calling from exome sequencing reads we used CLAMMS 
[115]. For base-level depth-of-coverage calculation, a higher mapping quality and exon 
window coverage distributions were normalized based on overall sequencing depth and GC 
content. For a given sample CLAMMS compares its coverage data to probability distributions 
which describe the expected depth of coverage depending on copy number state, at each calling 
window. A total of 1666 subjects were retained, after subjects with inflated CNV rates and 
systematic biases in coverage data that fall under the outlier category of dimensional reduction 
technique (PCA) were filtered out. 
3.2.3 Hardy–Weinberg equilibrium and quality control 
Statistical tests for Hardy–Weinberg equilibrium (HWE) is an important method to detect 
genotyping errors which has been widely applied in population based genetic association 
studies. According to HWE principle, genotypes aa, aA and AA of a bi-allelic variant occur 
with relative frequencies of p2, 2pq and q2, where p and q are the allele frequencies for a and A 
alleles. HWE analysis aims to detect significant deviations from the expected proportions. 
Similar to SNP arrays, NGS methods are also prone to genotyping error specially in the low-
coverage sequencing region and within the polymorphic locus of the genome which can deviate 
Ti/Tv ratio [87,116]. These problematic genotypes can affect the data quality for association 
studies. In Study II, we have applied HWE criteria implemented in vcftools for all the markers 
at a p-value <10-5. 
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3.2.4 Association statistics for common variants 
Single variant association tests were performed for common variants (MAF>5%) using logistic 
regression based on Wald test implemented in the EPACTS v3.3.0. Population substructure 
and unknown relatedness among the individuals in the cohort can have confounding effect on 
association studies [117]. Therefore, besides sex as a covariate twenty principal components 
(PCs) obtained from the kinship matrix which correct for relatedness was used in the model. 
The kinship matrix is obtained using vcf2kinship implemented in RVTEST [118]. In study II, 
in a case-control setting association tests were implemented for SNPs and INDELS in three 
study settings— PPMS vs PBC, RRMS vs PBC and PPMS vs RRMS and a p-value threshold 
of 5.5x10-7 is considered for significant association [119]. 
3.2.5 Annotation of relevant variants 
In addition to annotating the SNPs with dbSNP names, the disease relevant variants were 
annotated with ClinVar [120,121]. This helps to find the rare variants or mutations that are 
important or closely related to the disease in the study. The variants with biological impact 
(deleterious or non-synonymous) were functionally annotated using Annovar database which 
is used in the burden test to access the biological impact of rare variants in a gene  [122]. 
3.2.6 Association statistics for rare variants 
In cases of large sample size with large effect sizes, single-variant tests can be used for rare 
variants but in study II, with limited sample size we applied methods that analyse variants 
jointly. Joint analysis of rare variants in a defined region requires statistical tests that are 
profoundly different from association statistics used for testing common variants [123]. Since 
exome sequencing captures the variations that can be annotated at gene level, the functional 
and population genetics information can be integrated into the test. Furthermore, rare variants 
need to be combined at gene level or in a specific pathway to reach sufficient power. In study 
II, we included rare variants which are non-synonymous (changing protein codon) and have 
high biological impact [124]. Broadly, based on summarizing the variants in the gene, these 
methods can be classified into three— Burden tests, Variance Component tests and 
Combination tests [125]. 
Burden test summarizes all genotypes in a gene into one collapsed genetic score which can be 
applied directly in the association test. Combined and Multivariate Collapsing (CMC) test is 
an extended form of burden test and it is used in study II. It "collapses" all rare variants in the 
gene region based on its minor allele and "combines" with the remaining common variants in 
the gene region in a “multivariate” problem setting which can be tested for a trait for that the 
gene region [126]. When analysing large gene regions with many variants or with missing 
genotypes resulting from the sequencing studies with low coverage, the burden scores tend to 
underperform. Cases and controls with differential missing data can account for an increase in 
type 1 error [125]. On the other hand, variance component tests such as SKAT, allow a mixture 
of effects in the given set of rare variants [127]. They assume that selected rare variants can 
either increase or decrease the risk of disease and tests are designed to account for varying 
effect sizes. Combination tests such as SKAT-O applied in study II combine burden scores 
with variance component [128]. There are different procedures to combine these two statistics. 
In SKAT-O, a convex combination of statistics with the weight coefficient is applied which 
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can be illustrated as a test statistic given by ZO = αZS + (1 − α)ZB where ZS is a SKAT based 
variance component test statistic and ZB is a burden-like test statistic and the optimal weight 
coefficient α can be obtained by computing p values over a range of α values (0 ≤ α ≤ 1). 
 
3.3 MS TRANSCRIPTOME AND EQTL MAPPING  
3.3.1 Patient cohorts and RNA sequencing 
For the screening-phase of the eQTL study, RNA and DNA from PBMCs of 181 subjects were 
collected between 2001 and 2010, at the Neurology Clinic of the Karolinska University 
Hospital, Solna, Sweden (STOP-MS cohort). This cohort consisted of 117 MS patients, 28 CIS 
patients and 36 NIND (neurological diseases without an inflammatory state) patients. The reads 
from the RNA sequencing were mapped to hg19 genome (NCBI v37) using STAR aligner and 
quantified as counts per gene using HTSeq tool [129,130] To normalize the gene counts and to 
correct for the GC content and length biases, conditional quantile normalization (CQN) method 
was applied [131]. 
A separate cohort for validation with RNA and DNA isolated from sorted CD4+ and CD8+ 
cells were collected at the Neurology Clinic of the Karolinska University. Detailed report of 
the cohorts used in the screening phase and validation phase of this study is shown in Table 3 
of the paper III.  
3.3.2 Statistical framework for cis-eQTL analysis 
For each disease associated SNP, we selected genes that were expressed in 85% of samples 
and located 400-kb upstream and downstream of the SNP. The window size was decided based 
on the increased probability of finding cis-regulated genes at closer distances and to limit the 
number of SNP-gene tests, with an aim to reduce number of statistical tests performed. To 
calculate the strength and significance of the SNP-gene association, we implemented a two-
level analysis. First, the effect of selected variable identified in the component-based analysis 
is regressed out from the expression data normalized with Conditional Quantile Normalization 
(CQN) procedure [131]. Batch of RNA-Seq library preparation, age of individual at sampling, 
sex, disease-type, clinical course of MS and CIS and Interferon treatment were the variables in 
the meta-information investigated in the component-based analysis. Component-based analysis 
is explained in the later part of the methods under the section ‘Component based analysis and 
Analysis of variance’. Second,  spearman correlation is used to correlate residual values 
(obtained from regression) with genotype information obtained in the form of genetic additive 
model. In the additive model, genotypes are encoded numerically as 0,1 and 2. In case of a 
setting aa-aA-AA we used 0 for aa, 1 for aA, and 2 for AA, where allele ‘A’ is the risk allele 
associated to the disease. Permutation based p-value, with 15000 iterations was used to estimate 
the significance of the SNP-gene correlations. Non-parametric method was used to calculate 
False discovery rate (FDR) was implemented as described in [132] and to obtain sequential 
order as observed in Benjamini–Hochberg (BH) procedure, monotonicity is enforced in FDR 
estimation. A conservative selection criteria to reduce the false-positive findings; FDR<0.01 
were considered for significant eQTLs. The eQTL study is extended to the LD SNPs (r2 >0.5) 
in the genomic locus of the association. A stepwise association model was applied where we 
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regressed out the effect of most-significant LD SNPs, obtained from the LD SNP-gene 
correlation, along with other cofounders such as batch and disease-type from the normalized 
expression levels (CQN values). LD SNPs with a beta-value greater than the original MS SNP 
are reported and the functional annotation (DNASE I hypersensitivity, Enhancer specific marks 
and TF motifs) of these LD SNPs for different immune cells are further characterized for this 
region. Custom R scripts and python programs were written for eQTL analysis. 
3.3.3 Bayesian method for colocalization analysis 
Colocalization investigates if a single variant in a locus is responsible for both disease genetic 
association signal and eQTL signal. An approximate Bayes factor was used to compute the 
posterior probabilities for variants that are considered causal in both disease and eQTL analysis. 
The R package “coloc” is used in the analysis to calculate the posterior probabilities for 
independent signals (H3) and shared causal signal (H4) from both eQTL association and 
disease association in a given locus [133]. In figure 5, each trait (eQTL signal  and disease 
association signal) is represented as a binary vector (0,1) at 8 distinct genomic positions (SNP 
positions) which are shared between the traits. The value of 1 means that the SNP is causally 
involved in disease or an eQTL, 0 that it is not. The first plot shows the case where only one 
—  eQTL signal or disease signal have an association.  
 
Figure 5: A configuration setting to illustrate different hypotheses.  
[Figure adapted from “Giambartolomei C, Vukcevic D, Schadt EE, Franke L, Hingorani AD, Wallace 
C, et al. Bayesian Test for Colocalisation between Pairs of Genetic Association Studies Using Summary 
Statistics. PLoS Genet. 2014;10. doi:10.1371/journal.pgen.1004383”] 
The second plot shows that the causal SNP is different for the disease association dataset 
compared to the expression dataset. The third plot shows the configuration where both signals 
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localize through a single causal variant (4th genomic position). The test was done in loci within 
400-kb windows of MS-associated SNP and the prior probabilities (p1/p2 and p12) were set to 
the default values (p1/p2 = 1x10-4 and p12 =1x10-5). Approximate Bayes factor (ABF) was 
computed for H3 and H4 using “coloc.abf” function. Spearman correlated p-values obtained 
from the eQTL analysis and association P-values of all the SNPs in the disease locus were 
obtained from the immunochip study. Only regions with a minimum of 10 independent SNPs 
after LD pruning (LD, r2 <0.8) were  selected for this analysis and colocalization with eQTL 
SNPs were considered if H4.abf was found greater than H3.abf. 
3.3.4 Cell-type deconvolution and eQTL effect change 
An in silico cell-type deconvolution method called CIBERSORT was applied to CQN 
transformed expression values obtained from PBMCs, using the LM22 signature geneset (1000 
iterations) [134]. CIBERSORT allowed the estimation of the cell composition of PBMC from 
its PBMC gene expression profile using machine learning approaches. Cell types with a 
proportion >5% of the total PBMC mixture were aggregated into 5 groups: CD4 T cells, CD8 
T cells, Monocytes, B cells and NK cells. Correlation between estimated cell-type proportions 
and disease associated SNPs and HLA variants was estimated; those correaltions with a p-value 
<0.05 were considered significant. For variants/SNPs with significant association, the effect of 
the corresponding cell type along with RNA-Seq batch covariate was regressed out from the 
gene expression levels (CQN values); then, on the residual values, eQTL analysis was 
conducted to test if , after correcting for cell proportions, there was still a SNP-gene significant 
association. A stepwise association model was implemented for those SNPs associated with 
more than one cell type; in those cases cell-type proportions were added as covariates in the 
order of cell type-SNP association strength. 
3.3.5 Allele specific expression and analysis 
Unlike other methods in ASE, where ASE is applied at single heterozygous variants, here we 
implemented  phASER tool where it measures ASE at haplotype level [135,136]. This method 
use RNA-Seq data in combination with genomic data to phase heterozygous variants close to 
one another and aggregate the expression at the level of haplotypes. In our study we used 
genotyping data and PBMC RNA-Seq data used for eQTL study from 79 samples. Detailed 
steps of implementing genotyping data phasing and imputing procedures and ASE 
quantification steps are available here https://github.com/tojojames/PhaseImpute 
 
3.4 RNA SEQUENCING AND REPRODUCIBILITY  
3.4.1 Public RNA-Seq study 
Processed RNA-Seq data and raw FASTQ files were obtained from five studies— BodyMap, 
Evolution of Gene Expression, Human Protein Atlas, RNA-Seq Atlas and AltIso [137–141]. 
The human tissues include heart, kidney and brain (hypothalamus in the case of RNA-Seq 
Atlas). The meta-information included information about study source, tissue type, preparation 
(RNA extraction), layout (single or paired end), read length (paired-end set to 200) and total 
number of raw reads. 
  23 
3.4.2 RNA-Seq data analysis 
To study the effects of reprocessing raw sequence data, FASTQ files for human heart, kidney 
and brain samples from each of the five sources mentioned above were mapped to the human 
genome (GRCh37) using TopHat [142] and FPKM values were computed using Cufflinks 
[143]. To study the effects of log transformation and to reduce the effect of extreme outliers, 
we applied log transformation directly on the untransformed published FPKM/RPKM values. 
To correct systematic study-specific effects such as batch effects which can introduce biases in 
the expression data we applied ComBat function included in the sva R package [144]. 
3.4.3 Component based analysis and analysis of variance 
To study the consistency of clustering of tissue samples rather than by study we applied 
exploratory data analysis methods such as Principal component analysis (PCA). PCA is a 
simple eigenvector-based multivariate analyses method and it uncovers internal structure and 
variance in the data. In this gene expression dataset combined from different tissues, genes with 
highest PCA loadings are often tissue specific in nature. For this study, we examined 
correlations between principal component scores and study-dependent experimental factors or 
metainformation. Scores from the principal components which explain most of the variance, in 
total of at least 70% in the data, were selected for the correlation to metainformation. This helps 
to identify the factors or variables that contribute most to the variability of the data and similar 
approaches are applied in Study III to identify variables that influence the PBMC expression 
data obtained from patients. 
The advantage of Analysis of variance (ANOVA) is that it can measure variability in a 
quantitative variable such as gene expression and partition it into various identifiable sources 
from a well-designed  experiment. Primary sources of variability can include the experimental 
factors and random noise [145]. Since order matters in ANOVA test, we predefined an order 
that first includes the preparation variability such as layout, read length, RNA extraction 
method and number of raw reads and extended to the variability that cannot be controlled such 
as the study source and tissue types. 
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4 RESULTS AND DISCUSSION 
The work presented in this thesis mainly covers multiple areas of genetic, transcriptomic 
and post transcriptional regulation of miRNA in the disease susceptibility and progression 
of MS. 
4.1 MIRNAS IN POST-TRANSCRIPTIONAL REGULATION OF EAE (STUDY I) 
After immunization with MOG on 5 susceptible DA and 5 EAE resistant PVG rats, miRNAs 
were evaluated from lymph nodes seven days after immunization using small RNA sequencing. 
From a total of 329 miRNAs evaluated, 43 miRNAs were found to differ between pathogenic 
and resolving immune activation of EAE and majority of differentially expressed miRNAs 
(35/43) were upregulated in the EAE-susceptible DA strain. Using specific TaqMan qRT-PCR 
assays for miRNA , some of the differentially expressed miRNAs were validated. To identify 
relevant genes in the EAE regulation, we combined predicted miRNA targets with expression 
data from lymph node of DA and PVG rats, collected seven days after immunization. With this 
integrated approach, we found 109 genes targeted by the upregulated miRNAs in DA strain 
and 54 genes targeted by miRNAs upregulated in PVG strain. Additional in vitro validation 
experiments based on Luciferase reporter system were done for rno-miR-181a target genes 
such as Cxcr3, Prkcd, and Stat1 which have previously been reported in studies of MS and 
EAE. For highly expressed miRNAs, kinetics of its expression during the course of EAE was 
examined for a selected number of high-abundance miRNAs. For rno-miR-181a, rno-miR-128, 
and rno-miR-146a, the differential expression was observed at different time points post 
immunization (day 0, day 3, day 7 and day 25) and these miRNAs were primarily expressed in 
T cells. However, for rno-miR-223 and rno-miR-125b-5p differential expression is only 
observed on day 7 post immunization and these miRNAs were only expressed in non-
lymphocyte cell populations. 
From different expression kinetics of miRNA expression, it was determined that miRNAs have 
a role in regulating the ongoing inflammation and promoting disease. However, the role of 
individual miRNAs impacting the immune system and disease deserves further investigation. 
Using luciferase reporter system, we also validated three miRNA targets predicted for miR-
181a, indicating that the targets we identify are not likely false positives.  Since most of the 
miRNAs are conserved between human and rats, this study can provide some insights to the 
early development stages of MS. 
4.2 GENETIC VARIANTS ASSOCIATED TO PPMS AND RRMS (STUDY II) 
We explored potential genetic variants associated to MS using whole exome sequencing in 
cases and controls from PPMS, RRMS patients and population-based controls (PBC). With a 
cohort size of 552 PPMS, 575 RRMS and 575 age matched PBC; an association study was 
conducted at three levels—PPMS vs PBC, RRMS vs PBC and PPMS vs RRMS.  
We found less significant association of HLA class I in PPMS patients compared to RRMS. 
However, for both PPMS and RRMS we found strong association to HLA class II as previously 
reported in MS studies and the significance disappear when correcting for DRB1*15:01 as a 
covariate in the model. In addition to previously reported associations in MS — PHACTR2, 
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P2RX7 and PRKRA we report novel suggestive associations in CCL25, JMJD1C, LYZL2 and 
TIMM44 genes for RRMS and a significant indel association for PPMS in RP11-693J15.3 
locus and two non-synonymous suggestive associations in VCAN gene [37,146,147]. From the 
Copy Number Variants (CNVs) association analysis, we find LCE3C deletion less common in 
PPMS patients compared to PBC and RRMS. In rare variant association studies based on 
burden tests, we found genes showing trend of association— INO80D associated to RRMS and 
GBP5 associated to PPMS when compared to RRMS. Besides association studies, we also 
report the clinically relevant mutations observed in PPMS and RRMS cohort, which have 
resemblance to neurological disorders and MS.  
Deletion of CNV in PRKRA hase been reported to be associated with ankylosing spondylitis  
risk and PRKRA activates PRK which regulates the antiviral effects of interferon [148,149]. 
Pro-inflammatory effect of the P2X7 receptor that has been shown in various autoimmune 
diseases and is expressed on cells of the nervous system [150]. CCL25, a chemokine that 
signals through the receptor CCR9 and is mainly expressed in small intestine and thymus, 
which have a key role in T cell maturation and recruitment of T cells to the small intestine 
[151,152]. GBP5 stimulates NRLP3 inflammasome assembly which initiates an inflammatory 
response towards pathogens and tissue injuries [153]. NRLP3 has a role in the development of 
EAE [154]. LCE3C deletion is commonly found in the general population and deletion of 
LCE3C and LCE3B have been found to be associated to rheumatoid arthritis and psoriasis. 
Using a small cohort, we have studied the potential genetic variants associated to PPMS and 
RRMS patients using whole exome sequencing (WES). Since PPMS represent a small 
proportion of MS, genetic association to PPMS have not been adequately tested in the previous 
genetic association studies. In contrast to genotyping platforms, WES have better resolution at 
the coding region of the genome and have the possibility to identify the variants that are in low 
frequency [155]. In the gene region of PRKRA reported in the exome chip study we have found 
indels associated to RRMS patients [37].  Studies have proposed that a significant amount of 
high quality genotypes outside target regions of the exomes can be obtained from WES data 
and in our study some of suggestive associations are outside the target region [156]. However 
this study was limited by sample size and require independent cohorts for replication. 
4.3 DISEASE SPECIFIC EQTLS IN MS AND ITS RELEVANCE IN DIFFERENT 
CELL TYPES (STUDY III) 
eQTL analysis in PBMC samples from MS and CIS patients were performed for 109 non-HLA 
and 7 HLA markers from Immunochip study and resulted in 77 significant eQTLs using RNA-
Seq from PBMC samples (n=145). Permutation based methods for eQTL analysis were 
implemented after correcting for relevant covariates such as gender, diagnosis and batch of 
library preparation. Out of these some eQTL associated genes, for example CPTIB, MANBA, 
PLEK, METTL21B, AHI1, TNFRSF14, MERTK, IQCB1 and CLECL1 have been reported 
previously in studies from healthy individuals [44,157,158]. We also identified novel eQTLs; 
mostly non-coding RNAs, antisense transcripts and pseudogenes . "For 31 out of 47 non-HLA 
MS-eQTLs (66%) the transcription start site was located within 100 kb of the SNP, although 
70.2% of the total eQTLs did not affect the gene closest to the SNP. We identified eQTLs 
associated with cell proportions — rs2726518 - TET2 was associated with the proportions of 
monocytes, and rs6881706 -SPEF2 was correlated with the proportions of B cells, CD8+ cells 
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and monocytes. Bayesian test for colocalisation of eQTL and genetic signal were performed in 
22 MS susceptibility loci. 38 SNP-gene eQTLs were colocalised with the MS locus signal and 
two SNP-gene eQTLs — rs201202118-XRCC6BP1 and rs533646-AP002954.4.1, were not 
colocalised. Validation of MS eQTLs was perfomed in cell-type specific datasets- CD4, CD8 
cells (RNA-Seq) and B cells and monocytes (microarray) from controls. Forty percentage of 
the non-HLA SNP-gene eQTLs found in PBMCs were significant in at least three additional 
cell types and 74% were significant in at least one cell type. MS eQTL effect changes in 
monocytes collected from healthy individuals activated by different stimuli (LPS, 2h and 24h; 
IFN-γ, 24h) was compared to the unstimulated situation. eQTL pairs such as rs8042861-
IQGAP1 and rs941816-ETV7 showed increased effects in monocytes stimulated with IFN-γ 
and LPS (2h), rs2288904-SLC44A2 displayed an increased effect for IFN-γ, and rs2523822 
(HLA-A*02)-HLA-H for each of the three stimuli, while rs11052877-CLECL1 showed a 
decreased eQTL effects after the three stimulations. Thirty two of 73 eQTLs had an effect size 
increase in MS cases compare to the pooled cohort of MS and NINDs (non-inflammatory 
neurological disease) and genes in HLA region showed the highest (eg. HCP5). FCRL3 (eQTL 
gene), FCRL2 and FCRL5 genes in the rs706015 MS locus  were significantly downregulated 
in MS cohort compared to NINDs. Mapping to enhancer histone marks and predicted 
transcription factor binding sites added additional functional evidence for eight eQTL regions. 
We identified that rs71624119, shared with three other autoimmune diseases and located in a 
primed enhancer (H3K4me1) with potential binding for STAT transcription factors, 
significantly associates with ANKRD55 expression. 
We tested and replicated the eQTLs found from PBMCs in datasets from CD4 and CD8 T cells 
of MS patients and healthy controls from LCLs, primary B cells and monocytes, including 
monocytes activated by IFN-γ and LPS. Since there are overlap in risk genes between 
autoimmune diseases, the results reported in this study are relevant for other autoimmune 
diseases. This study can be a resource of information for further functional exploration of genes 
in animal models of MS and to mine the signaling pathways that are affected by MS associated 
variants. In our study we found that eQTL SNP for ANKRD55 was located in in an active 
regulatory region in PBMC and derived immune cells, with a possibility to bind to STAT1 
transcription factor. ANKRD55 was studied in EAE at protein expression level in neuron and 
microglia cultures, showing an active role in neuroinflammation and in humans the region is 
associated to Crohn’s disease, Rheumatoid Arthritis ad Juvenile Idiopathic Arthritis [159,160]. 
4.4 CONSISTENCY OF PUBLIC HUMAN TISSUE RNA-SEQ DATASETS 
(STUDY IV) 
In recent years, the accessibility of RNA-Seq based expression data have increased through 
different web repositories where users can get either precomputed gene expression values or 
raw sequence from various tissues collected from different organisms. Since universal 
standardization of RNA-Seq experimental protocols and equipment across laboratories is not 
practically possible, comprehensive studies of reproducibility focused on RNA-Seq data 
analysis pipeline are required. Furthermore, some studies have shown that publicly available 
RNA-Seq data sets from various laboratories and studies are at different phases not 
reproducible owing to the combined influence of reagent batch effects, differences in RNA 
extraction protocols, library preparation methods and computational processing [161–164].  
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Figure 6: Heat map with Spearman correlations between samples from brain, kidney and heart (A) 
Analysis of 11 data sets with published precomputed FPKM/RPKM values. (B) Analysis of log-
transformed published precomputed FPKM/RPKM values (C) Analysis of precomputed FPKM/RPKM  
values from four different studies after removal of batch effects using ComBat. 
To gain further insight into the reproducibility issues, we evaluated published human tissue 
expression profiles from brain, heart and kidney by quantifying factors contributing to 
variability between samples, using analysis of variance (ANOVA) and principal component 
analysis (PCA). From our analysis we found that reported FPKM/RPKM gene expression 
values are not comparable at global level. The read length was the factor that contribute to the 
highest variance for the reported gene expression data sets followed by library preparation 
method, layout and tissue type (Figure 6). However after log transformation and removal of 
batch effects, the data show global consistency. Besides the advantage of not missing gene 
identifiers for various studies, there is no additional contribution towards clustering by simply 
reprocessing the raw RNA-Seq data obtained in FASTQ format. This study demonstrates the 
usefulness of public RNA-Seq data and provide a positive outlook on the continuous efforts to 
secure and precautious on application of datasets collected from different laboratories. 
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5 CONCLUSIONS AND FUTURE PERSPECTIVE 
The underlying theme throughout this thesis has been that patient sample biobanks and omics 
based techniques are crucial in answering fundamental questions of disease biology and 
further improvements in this area can progress the future research in a faster pace. However 
in MS where the tissue for the disease is initiated and the processes leading to progression 
occur are not directly accessible in patients, it is important to use model organisms to 
understand the pathophysiology of the disease. Similar to all animal models in disease study, 
EAE has limitations; as it is heterogenous with respect to induction methods and pathological 
feature; and its utility depends on using the appropriate model to answer specific questions 
[174,175]. We have studied the role of miRNA in the epigenetic regulation of 
neuroinflammation within the setting of EAE. With the scope of NGS methods, we 
sequenced miRNAs from two inbred rat strains with higher quality and resolution which was 
superior to the array based or PCR based methods. One of the observation is that the 
dispersion in miRNA expression and the fold change of the top differentially expressed 
miRNAs is lower compared to gene expression. This might be due to feedback mechanisms 
that control miRNA levels or miRNAs might have a central role in maintaining the stability 
and plasticity of the immune system without directly initiating the disease. This study utilized 
the scope of prediction tools to identify miRNA targets. This was challenging as different 
tools predicted genes with slightly varying overlap on 43 miRNAs that we aimed to study. 
With the approach of integrating gene expression data to this study, we gained an added 
opportunity to select the genes that are both downregulated and targeted by miRNA, thereby 
helping to mine relevant pathways regulated by miRNAs in the experimental model of 
neuroinflammation. Using EAE, we also have shown that miRNAs have a crucial role during 
the early time-point of initiation and development of disease, which is not possible to study 
in human disease.  
One of the objective of studying the risk genes of PPMS was to fill the gaps in our 
understanding of the genetics of MS which was predominantly guided by RRMS patients 
with a distinctive clinical manifestation and a higher incidence in females. PPMS being 
invariably much smaller compared to RRMS, little is known about risk factors associated 
with the onset of PPMS [167]. Our study is limited by the cohort size, which restricted our 
findings to risk variants with high effect size. However by investigating the exomes of PPMS 
and RRMS we found a less strong association of HLA class I molecules in PPMS compared 
to RRMS. There are studies in animal model showing that CD8+ T cells with restricted MHC 
class I are capable of initiating the first subtle attack [168]. With whole exome sequencing 
and improved variant annotation, it is possible to study the association of the rare variants in 
the disease. Since we are restricted by the sample size, different gene based tests are applied 
to understand the combined effect of rare variants of higher functional impact. These methods 
depend to an extend on the rare variant annotation, scoring methods used to establish protein 
altering SNPs (eg. CADD score), inclusion criteria for rare variants in gene burden test (eg. 
at least 2 rare variants of impact in a gene) and selection criteria based on allele frequency 
for rare variants. In addition to the gene based tests reported in the study II, we have applied 
different settings for gene based test. In one of the setting of SKAT-O test, genes with at least 
two rare (MAF < 0.005) stop gain, splice donor, splice acceptor, or missense variants were 
selected where variants were predicted to have a damaging effect in protein level by setting 
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the CADD score > 20 or PolyPhen2 parameter set to “probably damaging”. This helped to 
find interesting genes with significant association for PPMS. 
Genome-wide scans, specially rare variant studies often are subject to a “winner’s curse” 
phenomenon resulting from the overestimation of genetic effects of associated variants and 
by underestimating sample sizes which can even result in opposite effects for the same 
variants in the replication study [169]. Since there are genome sequencing studies done in 
Swedish population, we can increase the sample size for population based healthy controls. 
To this end, for disease associated variants we have compared allele frequencies of healthy 
controls in our study cohort to allele frequency reported in SweGen project and found most 
of the reported variants having similar allele frequencies [170]. Moreover, for this study we 
have sequenced exomes with sufficient depth and followed GATK pipeline following 
specific parameters to improve the specificity and sensitivity of the variant discovery. This 
have resulted in finding mutations with high reproducibility and found the subject carrying 
the same mutations in CSF1R gene [171]. In one of the PPMS patients in this study, we found 
previously reported mutation NR1H3p.Arg415Gln, which was first identified and reported 
by Wang et al from the members of families with a progressive course of MS [172,173]. We 
have also scanned for mutations relevant for other neurodegenerative diseases in PPMS and 
currently we are examining their consequences in a clinical setting. 
Understanding the genetic risk architecture for an associated set of variants is important to 
elucidate the causes or pathological mechanisms occurring in a multifactorial disease such as 
multiple sclerosis. This objective was broadly achieved by characterizing the genotype-
phenotype relationships in MS through eQTL studies. With a high resolution transcriptomic 
data generated using NGS methods, applying appropriate statistical methods and integration 
of different cell type data we studied in depth the risk locus of 110 MS associated SNPs and 
7 HLA variants reported in ImmunoChip study. We have reported many novel and validated 
eQTLs interesting for future functional characterization of MS. Previous study have shown 
that eQTL genes are enriched in a cell-type specific manner for different diseases and in case 
of MS it was enriched in CD4 cells compared to monocytes [44,165]. In our study we 
extended the eQTL study to four PBMC derived immune cells with different stimulations for 
monocytes after the initial screening in PBMC of patients. About 74% of the eQTLs were 
replicated in at least one of the immune cells. This suggest that although gene-regulatory 
regions bearing disease risk variants are accessible in multiple immune cells, it may regulate 
gene expression in either a cell-type specific or condition-specific manner. With Genotype-
Tissue Expression (GTEx) project, our study can be further extended to more relevant tissues 
for disease such as brain. GTEx project report eQTLs based on bonferroni-corrected p-values 
which is a stringent criteria compared to the nominal p-value (p-value <0.05) criteria selected 
for replication part of our study [166]. We have also studied eQTL in the disease context by 
comparing MS cohort to pooled Cohort of MS and NINDs. Since cohort size of NINDs is 
small, these results need to be replicated and studied in larger cohorts. Two eQTLs were 
significant associated with cell proportions— rs2726518 associated with TET2 was 
correlated to proportions of monocytes, and rs6881706 associated with SPEF2 was correlated 
with the proportions of B cells, CD8 cells and monocytes. This is one of the first study where 
we investigated the effect of cell type proportions jointly with eQTL study. Similar to 
colocalization method applied in this study, it can be possible to model the SNP correlation 
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to cell types, gene expression and disease association and one can test the hypothesis that cell 
type proportion is leading the gene expression changes in PBMC. If cell type proportion have 
a leading role in regulating gene expression, one can expect cell-type specific methylation 
changes in these regions in the same primary tissue or in one of the derived cell types. With 
the epigenomic mapping of MS-associated variants, eight eQTL regions overlapped either 
with an H3K27ac or H3K4me1 active enhancer histone marks or with a DNase I 
hypersensitivity peak in monocytes, B cells, CD4 T cells and CD8 T cells and two eQTL 
regions overlapped with transcription factors. These epigenomic mapping provide some 
insights into complex regulatory mechanism localized to that particular region and help to 
prioritize appropriate cell type for translational studies. 
These are the exciting days to work in the field of computational biology. With the ever 
growing collection of biological data and repositories, it is possible to test different 
hypothesis and develop methods in a quick turnaround time. We utilized the possibilities of 
applying previously published data in all our studies and in particular to study the viability 
and biases of applying tissue specific RNA-Seq data that are publicly available. The idea of 
tissue specific RNA-Seq study originated at a time when reproducibility aspects of expression 
data collected from different laboratories was questioned and from the observations that we 
made in our in-house RNA-Seq studies. Our original expectation was; to gain higher accuracy 
and reliability, one have to redo the initial mapping procedures of RNA-Seq analysis pipeline 
for every publicly available datasets. To our surprise with slight pre-processing and 
correcting for batch effects, it was possible to show that published human tissue RNA-Seq 
expression measurements are relatively consistent, suggesting the high reliability of RNA-
Seq technology. These finding are been confirmed by recent studies and have extended to 
more recent datasets generated by GTEx, HPA and The Cancer Genome Atlas (TCGA) 
[176,177].  
It has been a decade since the first GWAS in MS was published. Since then further efforts 
were directed towards identifying more independent risk variants using larger cohorts. In 
recent MS Chip study, suggestive SNPs which do not meet genome-wide significance (p < 
5×10−8) contributed 9 % to the heritability so that now 48% of the heritability is estimated to 
have been explained [33]. Using WES, we have identified risk variants for RRMS and PPMS 
in suggestive and genome-wide significance level. Future association studies using large 
sample sizes, informed through WGS or WES may validate these new variants. One of the 
goal of association studies was to steer research toward novel genes involved in complex 
diseases. With increased number of identified risk loci, it is important to leverage relevant 
omics data to effectively prioritize and understand disease association signals and some of 
the approaches in the form of eQTL studies and WES (coding region of gene) are discussed 
in this thesis. eQTL studies can be extended to more relevant tissues, especially for the newly 
identified risk variants. Although we have shown the importance of eQTL studies in patient 
cohort, it would be beneficial to test this further in larger independent cohorts. We have 
studied the role of miRNAs in neuroinflammation and discussed challenges in understanding 
its role in disease regulation. Since miRNAs can target genes in a collaborative or competitive 
manner, it is difficult to attribute a miRNA-dependent dysregulation in disease and further 
studies in the form of gene (miRNA target) knock-down are required to completely 
understand the role of a selected miRNA in a disease. 
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